Outset Medical Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended March 31, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period fromtoCommission File Number: 001-39513 Outset Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware(State or other jurisdiction ofincorporation or organization)3052 Orchard Dr.San Jose, California(Address of principal executive offices) 20-0514392(I.R.S. EmployerIdentification No.) Registrant’s telephone number, including area code: (669) 231-8200 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirementsfor the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” inRule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new orrevised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May 1, 2026, the registrant had 18,537,241 shares of common stock, $0.001 par value per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited)Condensed Balance SheetsCondensed Statements of OperationsCondensed Statements of Comprehensive LossCondensed Statements ofConvertible Preferred Stock and Stockholders’ EquityCondensed Statements of Cash FlowsNotes to Unaudited Condensed Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and ProceduresPART II.OTHER INFORMATIONItem 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures PART I—FINANCIAL INFORMATION Outset Medical, Inc.Condensed Balance Sheets(in thousands, except per share amounts) Outset Medical, Inc.Condensed Statements of Operations(Unaudited)(in thousands, except per share amounts) Outset Medical, Inc.Condensed Statements of Comprehensive Loss(Unaudited)(in thousands) Three Months EndedMarch 31, Outset Medical, Inc.Condensed Statements of Convertible Preferred Stock and Stockholders’ Equity(Unaudited)(in thousands) Outset Medical, Inc.Condensed Statements of Convertible Preferred Stock and Stockholders’ Equity(Unaudited)(in thousands) Outset Medical, Inc.Condensed Statements of Cash Flows(Unaudited)(in thousands) Outset Medical, Inc.Condensed Statements of Cash Flows(Unaudited)(in thousands) Outset Medical, Inc.Notes to Unaudited Condensed Financial Statements 1. Description of Business Outset Medical, Inc. (the Company) is a medical technology company pioneering a first-of-its-kind technology to improveclinical outcomes in dialysis with less cost and complexity. Tablo® Hemodialysis System (Tablo), cleared by the U.S. Food andDrug Administration (FDA) for use from the hospital to the home, represents a significant technological advancement designed totransform the dialysis experience for patients and operationally simplify it for providers. Tablo serves as a single enterprise solutiondesigned to be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone.The integration of water purification and on-demand dialysate production in a single 35-inch compact console enables Tablo toprovide clinical and operational flexibility to customers. With a simple-to-use touchscreen interface, two-way wireless datatransmission and a proprietary data analytics platform, Tablo is a new holistic approach to dialysis care. The Company’sheadquarters are located in San Jose, CA. Liquidity Since inception, the Compa